Foghorn Therapeutics Inc. Impairment of Long-Lived Assets Held-for-use
Foghorn Therapeutics Inc. (FHTX) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2024-03-07
- Foghorn Therapeutics Inc. impairment of long-lived assets held-for-use for fiscal 2023 was $0.00.
- Foghorn Therapeutics Inc. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
- Foghorn Therapeutics Inc. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
- Foghorn Therapeutics Inc. impairment of long-lived assets held-for-use for fiscal 2020 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-07 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-07 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-09 |
| 2020-12-31 | $0.00 10-K/A · filed 2022-08-09 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |